CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies

CRISPR Therapeutics (CRSP) announced that it has entered into a collaboration deal with San Diego-based privately held company, Sirius Therapeutics, for developing and commercializing novel siRNA therapies.The strategic partnership is likely to diversify CRISPR Therapeutics’ pipeline by adding Sirius’s lead candidate, SRSD107, a next-generation, long-acting siRNA therapy, which is being developed in early-to-mid-stage studies for the treatment of thromboembolic disorders.SRSD107 targets Factor XI to treat t ...